Liminatus Pharma, Inc. (LIMN)
About Liminatus Pharma, Inc.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$10.2M
- Total assets
- $512.8K
- Market cap
- $6.4M
Source: SEC EDGAR · updated Jun 8, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $3.0M
- Operating income
- -$3.0M
- Net income
- -$10.2M
- EPS (basic)
- $-0.43
- EPS (diluted)
- $-0.43
Balance sheet
- Total assets
- $512.8K
- Current assets
- $500.6K
- Total liabilities
- $10.3M
- Current liabilities
- $10.3M
- Shareholders’ equity
- -$9.8M
Cash flow
- Operating cash flow
- -$10.0M
- Investing cash flow
- -$788.1K
- Financing cash flow
- $11.0M
- Net cash flow
- $281.3K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.4M
- EPS (diluted)
- $-0.43
- Shares outstanding
- 58.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 1, 2025
Liminatus Pharma, Inc. (LIMN) Stock Price
- Reported a net loss of $10.2M.
- Trading 100% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Liminatus Pharma, Inc..
Write a review
News about Liminatus Pharma, Inc.
News & sentiment via Polygon.io
Liminatus Pharma, Inc.: frequently asked questions
Is Liminatus Pharma, Inc. an American company?
Liminatus Pharma, Inc. is a US-based company headquartered in Cerritos, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Liminatus Pharma, Inc. headquartered?
Liminatus Pharma, Inc. is headquartered in Cerritos, California, United States.
Is Liminatus Pharma, Inc. publicly traded?
Yes — Liminatus Pharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol LIMN on the NASDAQ.
What does Liminatus Pharma, Inc. do?
Liminatus Pharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
